-$0.55 EPS Expected for CytomX Therapeutics Inc (NASDAQ:CTMX) This Quarter

Analysts predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will post ($0.55) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for CytomX Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.84) and the highest estimate coming in at ($0.29). CytomX Therapeutics posted earnings per share of ($0.72) in the same quarter last year, which would indicate a positive year over year growth rate of 23.6%. The company is scheduled to issue its next quarterly earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that CytomX Therapeutics will report full-year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($1.76). For the next fiscal year, analysts forecast that the business will report earnings of ($2.46) per share, with EPS estimates ranging from ($2.95) to ($2.10). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CytomX Therapeutics had a negative net margin of 163.18% and a negative return on equity of 90.62%. The company had revenue of $10.71 million for the quarter, compared to the consensus estimate of $23.58 million.

Several analysts have weighed in on the company. Nomura reaffirmed a “buy” rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research report on Sunday, August 11th. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. Wedbush lowered CytomX Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $25.00 to $8.00 in a research report on Monday, November 11th. BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. Finally, Guggenheim initiated coverage on CytomX Therapeutics in a research note on Wednesday, November 27th. They issued a “buy” rating and a $16.00 target price for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. CytomX Therapeutics has an average rating of “Buy” and a consensus price target of $18.56.

CTMX stock traded up $0.16 during trading on Friday, reaching $6.29. The company had a trading volume of 283,934 shares, compared to its average volume of 439,568. The company has a debt-to-equity ratio of 0.31, a current ratio of 4.40 and a quick ratio of 4.40. CytomX Therapeutics has a 52 week low of $5.10 and a 52 week high of $19.75. The business has a 50 day moving average of $6.17 and a 200 day moving average of $8.88. The company has a market cap of $285.78 million, a P/E ratio of -3.10 and a beta of 0.64.

Several hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP bought a new stake in shares of CytomX Therapeutics in the 1st quarter worth approximately $263,000. Strs Ohio grew its stake in shares of CytomX Therapeutics by 7.5% in the 2nd quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock worth $672,000 after buying an additional 4,200 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter worth approximately $70,000. DekaBank Deutsche Girozentrale increased its position in CytomX Therapeutics by 64.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 9,500 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in CytomX Therapeutics by 2.8% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 687,833 shares of the biotechnology company’s stock valued at $7,684,000 after buying an additional 19,000 shares in the last quarter. Hedge funds and other institutional investors own 78.89% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Read More: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.